Skip to content
10-Q

Quarterly Report

IMMIX BIOPHARMA, INC. IMMX

0001493152-25-021325

← back to feed
Filed
Nov 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 5, 2025 33.58M sh
Shares Diluted Q3 2025 · Sep 30, 2025 31.93M sh
Shares Diluted Q3 2025 · Sep 30, 2025 30.55M sh
Shares Diluted Q3 2025 · Sep 30, 2024 29.42M sh
Shares Diluted Q3 2025 · Sep 30, 2024 27.86M sh
Capex Q3 2025 · Sep 30, 2025 $567.8K
Capex Q3 2025 · Sep 30, 2024 $670.53K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$12.9M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$13.12M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $15.95M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $17.68M
Current Liabilities Q3 2025 · Sep 30, 2025 $10.85M
Current Liabilities Q3 2025 · Dec 31, 2024 $8.69M
Total Liabilities Q3 2025 · Sep 30, 2025 $11.82M
Total Liabilities Q3 2025 · Dec 31, 2024 $9.7M
Current Assets Q3 2025 · Sep 30, 2025 $16.58M
Current Assets Q3 2025 · Dec 31, 2024 $20.2M
Total Assets Q3 2025 · Sep 30, 2025 $20.08M
Total Assets Q3 2025 · Dec 31, 2024 $22.95M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.24
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.61
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.24
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.60
Eps Basic Q3 2025 · Sep 30, 2025 −$0.24
Eps Basic Q3 2025 · Sep 30, 2025 −$0.61
Eps Basic Q3 2025 · Sep 30, 2024 −$0.24
Eps Basic Q3 2025 · Sep 30, 2024 −$0.60
Sga Expense Q3 2025 · Sep 30, 2025 $3.08M
Sga Expense Q3 2025 · Sep 30, 2025 $8.53M
Sga Expense Q3 2025 · Sep 30, 2024 $2.95M
Sga Expense Q3 2025 · Sep 30, 2024 $7.77M
Rd Expense Q3 2025 · Sep 30, 2025 $4.58M
Rd Expense Q3 2025 · Sep 30, 2025 $10.53M
Rd Expense Q3 2025 · Sep 30, 2024 $4.45M
Rd Expense Q3 2025 · Sep 30, 2024 $9.92M
Net Income Q3 2025 · Sep 30, 2025 −$7.59M
Net Income Q3 2025 · Sep 30, 2025 −$18.75M
Net Income Q3 2025 · Sep 30, 2024 −$7.15M
Net Income Q3 2025 · Sep 30, 2024 −$16.8M
Operating Income Q3 2025 · Sep 30, 2025 −$7.66M
Operating Income Q3 2025 · Sep 30, 2025 −$19.06M
Operating Income Q3 2025 · Sep 30, 2024 −$7.39M
Operating Income Q3 2025 · Sep 30, 2024 −$17.69M
Revenue Q3 2025 · Dec 8, 2022 $20M